News & Updates
Filter by Specialty:
Use of RAS inhibitors associated with lower cancer risk in T2D
A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
Treatment with radiotherapy appears to result in more all-cause or prostate cancer-specific mortality (PCSM) compared with radical prostatectomy (RP), suggests a study.
